Boston, MA 10/09/2014 (wallstreetpr) – Biopharmaceutical firm Ruthigen Inc. (NASDAQ: RTGN), announced on 8th October that it is initiating Phase 1/2 clinical trials of its test drug candidate RUT58-60. The drug candidate is being developed as a potential systemic antibiotic, which can be administered during abdominal surgery. The drug maker has identified four sites within U.S to conduct these trials. These testing centres are located in “University of Virginia Medical Center, Helen Keller Hospital in Sheffield, University of South Alabama Medical Center, and Memorial Hermann Memorial City Medical Center”. It has also disclosed that it has initiated patient pre-screening activities at these sites.
Biotech firm Verastem, Inc. (NASDAQ:VSTM) announced on 8th October that it will be presenting data and results it has collated from its clinical testing of drug candidate VS-6063 at the 12th International Mesothelioma Interest Group Conference. The conference is being held in Cape Town, South Africa during the week of October 22-24, 2014. The test drug is being developed as a likely cure for treating patients suffering from “mesothelioma”. At the conference, the management team of the drug firm are likely to share the progress they have achieved in leveraging “cancer stem cells” as a viable treatment mechanism to treat this deadly form of cancer.
Engineering design firm AECOM Technology Corporation (NYSE:ACM) disclosed on 8th October that it has been awarded a contract by National Grid to work on its “Newtown Creek Renewable Natural Gas Project.” The engineering firm has been tasked to work with New York City Department of Environmental Protection on this project. The two entities are mandated to put together “engineering, procurement and construction services” for the project. The project is expected to commence in 2014 and is slated to end in 2016. The project plan of this innovative facility envisions the New York City authorities using the waste generated in the city to natural gas.
